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Colonization of the skin by Staphylococcus aureus is associated with exacerbation of atopic 
dermatitis (AD), but any direct mechanism through which dysbiosis of the skin microbiome may 
influence the development of AD is unknown. Here, we show that proteases and phenol-soluble 
modulin α (PSMα) secreted by S. aureus lead to endogenous epidermal proteolysis and skin 
barrier damage that promoted inflammation in mice. We further show that clinical isolates of 
different coagulase-negative staphylococci (CoNS) species residing on normal skin produced 
autoinducing peptides that inhibited the S. aureus agr system, in turn decreasing PSMα 
expression. These autoinducing peptides from skin microbiome CoNS species potently 
suppressed PSMα expression in S. aureus isolates from subjects with AD without inhibiting S. 
aureus growth. Metagenomic analysis of the AD skin microbiome revealed that the increase in 
the relative abundance of S. aureus in patients with active AD correlated with a lower CoNS 
autoinducing peptides to S. aureus ratio, thus overcoming the peptides’ capacity to inhibit the S. 
aureus agr system. Characterization of a S. hominis clinical isolate identified an autoinducing 
peptide (SYNVCGGYF) as a highly potent inhibitor of S. aureus agr activity, capable of 
preventing S. aureus–mediated epithelial damage and inflammation on murine skin. Together, 
these findings show how members of the normal human skin microbiome can contribute to 
epithelial barrier homeostasis by using quorum sensing to inhibit S. aureus toxin production. 
 







Atopic dermatitis (AD) is among the most common immune disorders and poses a serious risk of 
comorbidities and a major burden to patient quality of life (1, 2). Risk of developing AD is 
increased in patients with genetic defects in skin barrier function and is also associated with early 
life environmental exposure to various allergens (3–5). Furthermore, recent studies of the 
composition of the skin microbial community have suggested that a relative abundance of 
bacteria such as Staphylococcus aureus and coagulase-negative staphylococcal (CoNS) species 
may predict the development of AD (6, 7). These observations follow several decades of reports 
that S. aureus often colonizes lesions on the skin of patients with AD (8) and positively 
correlates with disease severity (9–11). Despite the large body of work to identify genetic, 
environmental, and microbial risk factors that may cause AD, there is as of yet no validated, 
cohesive hypothesis to link these observations together into a unifying pathophysiologic 
mechanism. 
 
AD is characterized by a T helper 2 (TH2)–dominant immune phenotype. Patients with AD have 
increased amounts of TH2 cytokines such as interleukin-4 (IL-4) and IL-13 in the skin (12, 13). 
These cytokines promote decreased function of the skin barrier by inhibiting expression of 
filaggrin (14) and suppressing expression of antimicrobial peptides such as cathelicidin and β-
defensin-2. These defects promote dysbiosis of the skin bacterial community and enhanced 
colonization by S. aureus (15). Therapy targeting the IL-4 receptor α results in a substantial 
improvement in disease (16). The strong association between TH2 cytokine activity, barrier 
function, antimicrobial activity, and disease outcome supports efforts to define a causal link 
between these essential epidermal functions. However, it has not been shown how dysbiosis can 
promote or enable skin disease. 
 
Recent evidence has demonstrated that virulence factors produced by S. aureus, such as phenol-
soluble modulin α (PSMα) and PSMδ, can promote skin inflammation in mice (17–20). PSMs 
represent a family, often cytolytic, of peptides secreted by S. aureus and include PSMα1 to 
PSMα4, PSMβ1 and PSMβ2, PSMδ, and the recently observed PSM-mec. In addition to 
promoting inflammation, S. aureus virulence factors can also cause epidermal barrier disruption, 
a key element in the pathophysiology of AD, by inducing expression of endogenous proteases 
from keratinocytes (21). Other studies have shown that the potential for S. aureus to induce 
inflammation can be linked to genetic disorders in barrier assembly including mutations in the 
filaggrin gene and the penetration of bacteria into deeper layers of the skin (22, 23). Together, 
we hypothesized that skin inflammation is promoted by penetration of S. aureus below the 
epidermis and that this may be caused by the action of S. aureus to increase protease activity in 
keratinocytes, thus disrupting the skin barrier. 
 
This investigation sought to identify the molecular mechanism responsible for the deleterious 
effects of S. aureus on the epidermal barrier and further define how dysbiosis at the skin surface 
permits this microbe to promote inflammation. Our study uncovers a previously unappreciated 
interaction between microbial communities on the skin that reinforces the need for microbial 
diversity in AD. These data show that interspecies quorum sensing between bacteria on human 





PSMα and proteases produced by S. aureus induce epidermal barrier damage 
 
To understand the potential role of S. aureus PSMs on epidermal barrier function, we assessed 
normal human epidermal keratinocytes (NHEKs) for their capacity to express proteolytic activity 
when exposed to S. aureus PSMs. Treatment with conditioned medium from wild-type S. 
aureus (USA300 LAC) or the same strain with targeted deletions in either the psmα or psmβ 
operons revealed that psmα was required for induction of trypsin-like serine protease activity and 
increased mRNA expression of kallikrein 6 (KLK6) (Fig. 1, A and B). We next tested synthetic 
PSMα1 to PSMα4 and PSMβ2 peptides that we synthesized on the basis of the genes encoded 
within the psmα and psmβ operons and found that all PSMα peptides could stimulate trypsin 
activity, whereas PSMβ2 could not (Fig. 1C). PSMα3, the strongest inducer of protease activity 
in NHEKs, induced trypsin activity and KLK6 mRNA expression in NHEKs in both a dose- and 
time-dependent manner and also induced cytokine production [IL-6, tumor necrosis factor α 
(TNFα), and IL-1α] in human keratinocytes (fig. S1, A to D). Furthermore, transcriptional 
profiling by RNA sequencing (RNA-seq) of NHEKs exposed to PSMα3 showed that this toxin 
had a broad effect on expression of several genes related to the skin barrier, including multiple 
proteases [KLKs and matrix metalloproteinases (MMPs)], components of the physical barrier 
(filaggrin, desmoglein-1, loricrin, involucrin, and keratins), antimicrobial peptides, and 
proinflammatory cytokines (Fig. 1, D and E, and fig. S1E). Deletion of psmα, but not psmβ, also 
reduced the production of IL-6, TNFα, and IL-1α from NHEKs (fig. S1, F to H). 
 
To validate the role of the psmα operon on the epidermal barrier in vivo, mice were colonized on 
the skin surface for 72 hours with equal numbers of the S. aureus USA300 LAC wild type or the 
corresponding psmα mutant strain. S. aureus induced erythema, scaling, and epidermal 
thickening of murine skin in a psmα-dependent manner (Fig. 1F). Despite increased epidermal 
thickness, we observed an increase in TEWL, a well-established method to assess skin barrier 
damage after exposure to wild-type S. aureus, but not when psmα was absent (Fig. 1G). Skin 
barrier disruption of a fully differentiated epidermis in vivo was also dependent on the 
expression of protease activity by S. aureus. Using a mutant strain of S. aureus derived from the 
wild-type USA300 LAC (AH1263) parent strain that lacks all 10 major secreted proteases 
(AH1919) (24), we showed decreased injury and improved TEWL when S. aureus lacked 
protease activity, despite fully intact psmα expression (Fig. 1, F and H). An increase in epidermal 
trypsin activity, epidermal thickness, Klk6, and Il6, Il17a, and Il17f transcript expression was 
observed in mice exposed to wild-type S. aureus, but not when exposed to psmα or protease-
deficient strains (fig. S2). A decreased inflammatory response to the protease-deficient mutant 
contrasted with the response of cultured NHEKs that showed only minor differences in 
endogenous protease activity induction (21) and no change to KLK6 expression or cytokine (IL-
6, TNFα, and IL-1α) responses when conditioned medium from the protease-deficient mutant 
was applied (fig. S1, I and J). This suggests that S. aureus protease activity is necessary for psmα 
to activate keratinocytes when an intact stratum corneum is present. Despite changes in the skin 
barrier and inflammatory milieu, S. aureus survival on skin was not influenced by deletion 
of psmα or protease activity (Fig. 1, I and J). Together, these data show that both production of 
PSMα peptides and protease activity from S. aureus result in damage to the epidermal barrier, a 




Figure 1. S. aureus PSMα induces keratinocyte protease activity and disrupts epithelial barrier 
homeostasis.  
NHEKs were stimulated with 5% S. aureus USA300 LAC (SA) supernatant from overnight cultures [1 × 
109 colony-performing units (CFU)] of wild-type (WT) and psmα (Δpsmα) or psmβ (Δpsmβ) knockout strains for 24 
hours. Both (A) trypsin activity and (B) KLK6 mRNA expression compared to the housekeeping gene GAPDH were 
analyzed (n = 4). (C) PSM synthetic peptides were added to NHEKs for 24 hours to analyze changes in trypsin 
activity (n = 4). (D) Transcript analysis by RNA-seq and (E) gene ontology (GO) analysis of genes that changed ≥2-
fold 24 hours after PSMα3 treatment. The number of genes in each category shown in parentheses. (F) Eight-week-
old male C57BL/6 mice were treated for 72 hours with 1 × 107 CFU SA WT (USA300 LAC) and corresponding SA 
Δpsmα, or SA USA300 LAC WT (AH1263) and corresponding SA Δproteases [SA WT in (F) representative of both 
SA WT strains]. Bacterial growth medium was used as a vehicle control. Dashed lines indicate treatment area. Scale 
bars, 200 μm (n = 6). (G to J) Transepidermal water loss (TEWL) or measurement of CFU/cm2 on mice after 72-
hour treatment with initial 1 × 107 CFU of (G and H) SA WT (USA300 LAC) and corresponding SA Δpsmα or (I 
and J) SA WT [USA300 LAC (AH1263)] and corresponding SA Δproteases (n = 6). All experiments are 
representative of three independent experiments. Error bars are SEM. One-way ANOVA was used to determine 
statistical significance. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Ctl, control. 
 
Staphylococcus epidermidis autoinducing peptide inhibits S. aureus agr activity 
 
Both the S. aureus PSMα peptides and secreted proteases are under regulation of the accessory 
gene regulatory (agr) quorum sensing system. S. aureus clinical isolates have been found to have 
four distinct agr types, with agr type I being the most prominent in AD subjects (25, 26). A S. 
epidermidis agr type I laboratory isolate was previously revealed to produce an autoinducing 
peptide that could inhibit S. aureus agr types I to III but not type IV, but little is known of the 
influence of other agr types or the skin commensal community as a whole on S. aureus 
agr activity (27). To investigate this, conditioned culture supernatants from defined laboratory 
strains of S. epidermidis with agr types I (RP62A), II (1457), or III (8247) were first tested with 
a S. aureus USA300 LAC agr type I P3-YFP reporter strain to explore whether S. epidermidis 
agr activity could influence the S. aureus agr system. S. epidermidis agr type I inhibited S. 
aureus agr activity, whereas S. epidermidis agr types II and III had little effect (Fig. 2, A and B). 
Targeted deletion of the S. epidermidis (RP62A) agr type I autoinducing peptide within 
the agrD gene region abolished the capacity of S. epidermidis to inhibit S. aureus agr activity 
(Fig. 2C). Furthermore, we observed that the increase in NHEK trypsin activity was inhibited 
when S. aureus was cultured in the presence of supernatant from wild-type S. epidermidis 
agr type I, but not by S. epidermidis lacking this autoinducing peptide (Fig. 2D). These 
experiments demonstrate that some S. epidermidis laboratory strains could inhibit the capacity 
of S. aureus to induce keratinocyte trypsin activity and may therefore be relevant to 
inflammation in AD. 
 
CoNS prevent S. aureus damage to AD skin 
 
Having established the potential for a S. epidermidis agr type I strain to decrease the capacity 
of S. aureus to induce protease activity in human keratinocytes, we next investigated the 
abundance of S. epidermidis agr types on patients with AD. We analyzed previously published 
metagenomic data available from the skin microbiome of 5 healthy subjects and 11 subjects with 
AD (28). Of the 60 S. epidermidis strains detected on AD skin, the most frequent agr type was 
that of agr type I (Fig. 2E). Data were next stratified on the basis of severity [objective SCORing 
Atopic Dermatitis (oSCORAD)], and results were pooled from seven body sites. Comparison of 
the abundance of S. epidermidis agr type I to S. aureus showed that S. epidermidis agr type I 
became relatively less abundant in AD subjects with increased disease severity across all body 
sites (Fig. 2, F and G). Analysis by body site showed a similar trend at all locations, with the 
most frequent affected sites of the antecubital crease and popliteal crease showing the most 
notable association with global severity (fig. S3). These observations suggested that the relative 
abundance of S. epidermidis agr type I compared to S. aureus in the AD skin microbiome is 
associated with clinical disease. This association is consistent with a potential quorum sensing 
mechanism that would require an increased ratio of autoinducing peptides from S. epidermidis to 
inhibit S. aureus disease-promoting protease and toxin production. 
 
 
Figure 2. S. epidermidis agr type I autoinducing peptide characterization and deficiency in AD 
skin. 
(A) SA USA300 LAC agr type I P3-YFP activity after overnight culture (1 × 109 CFU) with 25% supernatant from 
overnight culture of S. epidermidis (S. epi) agr types I (RP62A), II (1457), and III (8247) (n = 4). (B) Structure of S. 
epidermidis agr type I autoinducing peptide (AIP). (C) Analysis of agr activity as in (A) with S. epidermidis agr 
type I (RP62A) WT or autoinducing peptide knockout (ΔAIP) strain supernatants (n = 4). (D) NHEK trypsin activity 
after culture for 24 hours with 5% SA supernatant grown overnight with or without S. epidermidis agr type I 
(RP62A) WT or autoinducing peptide knockout (ΔAIP) (n = 4). (E) Number (#) of S. epidermidis agr types I to III 
strains found on AD skin from metagenomic dataset. (F and G) Ratio of S. epidermidis agr type I to SA relative 
abundance on the combined analysis of all sites sampled from 5 healthy individuals and 11 AD subjects during flare 
and ranked from “least severe” to “most severe” based on oSCORAD. (H) Analysis of agr activity as in (A) after 
coculture overnight with 25% supernatant of overnight cultures (1 × 109 CFU) of clinical CoNS strains (n = 3). (I) 
Assessment of autoinducing peptide coding regions in agrD gene of the inhibitory CoNS strains. All experiments 
are representative of three independent experiments. All error bars are SEM. One-way ANOVA or an 
(nonparametric) unpaired Kruskal-Wallis test in (G) was used to determine statistical significance. *P < 0.05, **P < 
0.01, ***P < 0.001, ****P < 0.0001. 
 
Figure 3. Inhibition of S. aureus agr activity by clinical S. hominis isolate correlates with 
prevention of skin barrier damage and inflammation. 
(A to C) SA USA300 LAC agr type I pAmi P3-Lux reporter strain (AH2759) (1 × 107 CFU) combined with or 
without live S. hominis C5 (1 × 107 CFU) was applied to murine back skin for 72 hours, and SA agr activity was 
assessed by changes in luminescence. Images are representative of n = 5; dashed boxes indicate treatment area. 
(D to G) Murine back skin after 72-hour bacteria treatment, assessed for changes in TEWL, trypsin activity, 
and Klk6 and cytokine (Il6, Il17a, and Il17f) mRNA expression normalized to housekeeping gene Gapdh (n = 5). 
(H) Relative abundance of SA psmα mRNA isolated from swabs of healthy (n = 6) and AD nonlesional and lesional 
skin (n = 5). (I) Detection of SA PSMα3 by immunofluorescence in epidermis of AD lesional skin (representative 
image with scale bar, 100 μm). (J) Clinical SA isolates from 11 patients were grown up to 18 hours (1 × 109 CFU) 
with or without 25% S. hominis C5 supernatant. psmα mRNA expression was measured at 8 hours, whereas trypsin 
activity was assessed from NHEKs treated 24 hours with 18-hour cultured SA (5%) supernatant (n = 3). (K) 
Immunoblot of culture supernatant from clinical SA isolate AD 38 grown overnight (1 × 109 CFU) with or 
without S. hominis C5 supernatant and probed for PSMα3. (L to N) SA AD 38 (1 × 107 CFU) was applied to murine 
back skin with or without S. hominis C5 (1 × 107 CFU) for 72 hours (n = 5) (dashed boxes indicate treatment area). 
Changes in CFU/cm2 of SA and CoNS, and TEWL are shown. All experiments are representative of two 
independent experiments. Error bars represent SEM. Student’s t tests, Pearson correlation coefficient (J), and an 
(nonparametric) unpaired Kruskal-Wallis test (H) were used to determine statistical significance. *P < 0.05, **P < 
0.01, ***P < 0.001, ****P < 0.0001. 
 
Having established the function of a laboratory strain of S. epidermidis to inhibit the capacity 
of S. aureus to damage the epidermis, and observing that there was a lack of S. epidermidis 
agr type I strains relative to S. aureus in more severe AD, we next sought to determine whether 
quorum sensing interactions might exist between other members of the skin microbiome and S. 
aureus. We screened multiple clinical CoNS isolates from AD and healthy subjects for the 
capacity of culture supernatants from these isolates to inhibit S. aureus agr activity. This 
experiment revealed that diverse species other than S. epidermidis, including Staphylococcus 
hominis, Staphylococcus warneri, and Staphylococcus capitis, have potent inhibitory activity 
against S. aureus and encode putative autoinducing peptides (Fig. 2, H and I). We screened 144 
clinical CoNS isolates from healthy individuals and 288 isolates from both nonlesional and 
lesional AD skin swabs and found that the frequency of CoNS strains that could inhibit S. aureus 
agr activity was similar across all subjects regardless of disease state (fig. S4, A and B). As 
CoNS from healthy skin often have the capacity to inhibit growth of S. aureus (29), culture 
supernatant was used at a 25% dilution that effectively inhibited agr but did not inhibit S. 
aureus growth (fig. S4C). These findings suggest that multiple diverse members of the skin 
microbial community may contribute to suppressing S. aureus agr activity. 
 
To establish whether quorum sensing interactions between CoNS and S. aureus can occur on live 
skin, S. aureus agr activity was assessed on mice by In Vivo Live Imaging (IVIS) using the S. 
aureus USA300 LAC agr type I P3-Lux promoter strain. We chose S. hominis C5 as a model 
clinical CoNS isolate for the remainder of this study as this strain potently inhibited S. aureus 
agr type I activity but did not have antimicrobial activity against S. aureus, thus permitting 
accurate assessment of agr activity. Application of live S. hominis C5 together with S. aureus to 
mice at a 1:1 ratio resulted in potent inhibition of agr activity, inflammation, TEWL, trypsin 
activity, and decreased Klk6 and cytokine expression (Fig. 3, A to G). At a higher S. aureus to S. 
hominis ratio (10:1), the protective activity of S. hominis was lost (fig. S5, A and B). This was 
similar to the increase in AD severity seen in subjects with an increased ratio of S. aureus (Fig. 
2F). Use of a clinical CoNS isolate that did not inhibit agr activity (S. epidermidis A11) did not 
prevent the capacity of S. aureus to promote barrier damage and inflammation (fig. S5, C and D). 
Co-application of S. hominis C5 did not decrease the abundance of S. aureus (fig. S5, B and D). 
 
Sequence analysis of metagenomic data from patients with AD revealed that there was diversity 
in S. aureus agr types on patients with AD, with the most common being agr types I and II (fig. 
S6). We sought to determine whether S. aureus clinical isolates had an agr type allowing them to 
express PSMα peptides and induce damage to the epidermis similar to the laboratory isolate 
USA300 LAC. We screened skin swabs from healthy, nonlesional, and lesional patients with 
AD. The S. aureus psmα operon transcript was much more abundant in samples from patients 
with AD (Fig. 3H). S. aureus PSMα3 protein deposition was detected in the epidermis of lesional 
AD skin sections by immunohistochemistry (Fig. 3I). Functional screening of 11 distinct 
clinical S. aureus isolates obtained from the lesional skin of 11 subjects with AD demonstrated 
that all of these strains were able to induce trypsin activity in NHEKs, and that the mRNA 
expression of the psmα operon correlated with the bacterial capacity to induce trypsin activity 
(Fig. 3J). S. hominis C5 supernatant inhibited S. aureus agr types I to III, but not type IV, and all 
of the 11 S. aureus isolates from AD subjects were identified as being agr type I or II (fig. S6). 
We found that S. hominis C5 could also prevent PSMα3 protein expression in a potent S. 
aureus AD isolate (AD 38) (Fig. 3K). Last, co-colonization of murine back skin with AD 38 and 
live S. hominis C5 (1:1 ratio) was shown to inhibit skin injury and inflammation without 
changing S. aureus abundance (Fig. 3, L to N). This treatment also prevented AD 38–induced 
trypsin activity, Klk6 expression, and cytokine expression (fig. S5, E to G). Overall, these data 
confirm expression of PSMα on AD skin and support the clinical relevance of our observations 
that CoNS can inhibit the agr activity and prevent S. aureus virulence factor production. 
 
Purification of an autoinducing peptide from S. hominis and confirmation of activity 
 
To further validate the conclusion that S. aureus agr inhibition was due to autoinducing peptide 
expression from the microbiome of human skin, we next identified the autoinducing peptide 
from the S. hominis C5 clinical isolate. This was accomplished by several initial biochemical 
isolation steps from crude S. hominis C5 supernatant followed by liquid chromatography–mass 
spectrometry (LC-MS) of enriched fractions. Our purification and sequence analysis detected an 
autoinducing peptide sequence (S-Y-N-V-C-G-G-Y-F) with a cyclic ring between the C and F 
amino acids (Fig. 4, A to C). The identified sequence was consistent with an autoinducing 
peptide in the agrD coding region predicted by genomic DNA sequencing (Fig. 2I). 
 
To validate that this S. hominis C5 autoinducing peptide could inhibit S. aureus agr activity, we 
generated a synthetic peptide and added it to the agr reporter strain. The synthetic autoinducing 
peptide potently inhibited S. aureus agr activity in a dose-dependent manner and showed a 
median inhibitory concentration (IC50) of 0.6243 nM (Fig. 4D). The synthetic autoinducing 
peptide also inhibited the capacity of this S. aureus strain to induce trypsin activity in NHEKs 
(Fig. 4E). When the synthetic autoinducing peptide was directly added to mouse skin colonized 
with S. aureus, agr activity was inhibited (Fig. 4, F and G). The synthetic autoinducing peptide 
also inhibited TEWL, Klk6, and cytokine expression induced on murine skin by S. 
aureus without inhibiting S. aureus abundance (Fig. 4, H to J, and fig. S7). These data confirm 
that an autoinducing peptide from a CoNS species resident on human skin can inhibit 
the agr activity of S. aureus, supporting the conclusion that interspecies quorum sensing 





Figure 4. Identification of an autoinducing peptide from a clinical S. hominis isolate that 
inhibits S. aureus agr activity. 
(A) Determination of S. hominis C5 autoinducing peptide sequence as SYNVCGGYF. The MS-MS spectrum 
obtained with the synthetic peptide is shown. Bolded fragment peaks and those indicated in color were identified in 
the MS-MS spectra for both the synthetic peptide and the spent growth medium sample (with difference in mass of 
<5 parts per million). Only matching fragments above 15% abundance are shown. Key features used for 
identification were the y5 (blue), y6 (red), and y7 (green) fragments of the cyclic autoinducing peptide. The selected-
ion chromatograms for mass/charge ratio (m/z) 991.3984 ± 5 ppm for (B) bacteria culture and (C) synthetic 
autoinducing peptide in growth medium confirmed the retention time (TR) and accurate m/z of the predicted 
autoinducing peptide sequence. (D) Analysis of S. hominis C5 synthetic autoinducing peptide on SA USA300 
LAC agr type I P3-YFP activity after an overnight culture (1 × 109 CFU) and IC50 value indicated by dotted lines at 
midpoint of the curve. (E) Measurement of NHEK trypsin activity after 24-hour incubation with 5% supernatant 
from overnight culture of SA with or without S. hominis C5 autoinducing peptide (1 × 109 CFU) (n = 4). (F to H) 
SA USA300 LAC agr type I pAmi P3-Lux with or without S. hominis C5 synthetic autoinducing peptide was 
colonized (1 × 107 CFU) on murine back skin for 48 hours followed by analysis of agr activity (luminescence) and 
representative pictures of murine back skin after treatment (dashed lines represent treated areas) (n = 5). (I and J) 
SA CFU/cm2 and TEWL after treatment with S. hominis C5 synthetic autoinducing peptide. Data are representative 
of two experiments. Error bars are SEM. One-way ANOVA and Student’s t tests were used to determine statistical 




In this study, we provided two interrelated mechanisms that shed new light on the development 
and control of AD. Our findings show that S. aureus PSMα peptides directly act on human 
keratinocytes, the main cell type responsible for establishment of the physical barrier of the skin. 
Exposure to PSMα leads to increased proteolytic activity in the epidermis, breakdown of the 
epidermal barrier, and subsequent skin inflammation. This observation explains how S. aureus 
residing on the skin surface can promote and exacerbate disease in the absence of the deep tissue 
invasion that defines infection. The second main finding from this study is based on earlier 
observations that PSMα is under control of the quorum sensing agr system (30). As autoinducing 
peptides from some laboratory bacterial species have been found to repress the S. aureus agr 
system (27, 31, 32), we hypothesized that such an interspecies interaction within the human skin 
microbiome may be a normal event to maintain homeostasis even if colonization with S. 
aureus can occur. Our data demonstrated that several different CoNS species, but not all strains 
within these species, encode autoinducing peptides that repress S. aureus agr activity. We 
showed that a beneficial CoNS strain or the synthetic CoNS autoinducing peptide was capable of 
inhibiting skin inflammation induced by S. aureus. We found that the stoichiometry of these 
interspecies interactions is unfavorable during disease flares in patients with AD, potentially 
indicating that when dysbiosis becomes extreme, these subjects then become exposed to PSMα. 
This is consistent with the direct observation of PSMα mRNA and protein deposition on lesional 
AD skin, an event that would not occur if CoNS autoinducing peptides were sufficiently 
abundant to suppress PSMα expression. Together, these observations show a previously 
unrecognized mechanism by which the diverse members of the skin microbiome can inhibit the 
disease-promoting activity of S. aureus. This observation could potentially explain why loss of 
bacterial diversity from excess abundance of S. aureus is strongly associated with increased 
disease severity. 
 
S. aureus–secreted proteases, including the V8 protease, can directly cause skin barrier damage 
in mice (33) and play a vital role for S. aureus penetration into deeper layers of the epidermis 
and dermis, an event that triggers maximal induction of TH2 and TH17 inflammatory responses in 
murine AD models (22, 23). In this study, we found that S. aureus subverted the healthy murine 
epidermal barrier by the combined action of protease activity and production of PSMα 
peptides. S. aureus–secreted proteases appeared essential to enable PSMα peptides to induce 
inflammation in vivo, where an intact stratum corneum protects underlying live keratinocytes. In 
vitro, S. aureus proteases had little to no effect on human keratinocytes, whereas PSMα 
expression was the major factor responsible for inducing keratinocyte trypsin activity. This 
suggests that S. aureus–secreted proteases are required for S. aureus to penetrate the skin in 
order for PSMα to stimulate keratinocytes. This process of inter-kingdom signaling explains how 
minor colonization by S. aureus could be amplified to promote major defects in the skin barrier. 
Future work is needed to better understand how S. aureus can penetrate the epidermal barrier 
including analyzing exactly what contribution each of the 10 known secreted S. aureus proteases 
including aureolysin, V8, staphopain A/B, and SplA-F have in inducing skin barrier damage. 
 
We confirmed previous reports that PSMα peptides could induce an array of proinflammatory 
cytokines, including IL-6, IL-1α, and TNFα, in human keratinocytes and skin. Keratinocyte 
secretion of IL-1 type cytokines was recently shown to be important for subsequent TH17 
responses in murine skin (17, 18). TH17 responses have also been found to be clinically 
important in acute AD (34–36) and may explain an important component of how both S. aureus 
agr–regulated toxins such as PSMα and secreted proteases stimulate skin inflammation. Previous 
work has shown that a more TH2-dominant response in mice is observed after S. 
aureus colonization of ovalbumin-sensitized mice lacking filaggrin (22). This further supports 
the important interplay between environment, host genotype, and S. aureus colonization to drive 
human AD. 
 
Here, we validated that the S. epidermidis agr type I autoinducing peptide was active against S. 
aureus USA300 LAC agr type I and protective for human keratinocytes, whereas S. epidermidis 
agr types II and III were not active. Analysis of clinical samples from AD subjects demonstrated 
the presence of these strains on human skin and suggested that disease flare severity correlates 
with a decrease in the abundance of S. epidermidis agr type I relative to S. aureus, a condition 
that would promote PSMα expression and disease progression. One limitation of the current 
study is that the absolute abundance of autoinducing peptides and production of PSMα peptides 
were not measured during the course of disease flares. Such information would provide 
important supporting evidence that the quorum sensing interaction causes disease or promote 
remissions. In addition, despite the benefit displayed in this study by restoring commensal CoNS 
strains to the diseased skin phenotype to prevent S. aureus agr activity, more work is necessary 
to use this treatment as a potential therapeutic option. Several studies have eluded to biofilm 
formation being inversely regulated by the S. aureus agr system, with biofilms promoted by 
inhibition of agr (37, 38). Biofilms have been detected on subjects with AD (39), and their 
presence increases resistance of S. aureus to killing by host antimicrobials such as LL-37 (40). 
Therefore, although CoNS autoinducing peptides appear to be protective against skin 
inflammation induced by S. aureus, it is also possible that this promotes persistent colonization. 
This study also did not examine the efficacy of transplanted autoinducing peptide inhibitory 
CoNS strains to survive on diseased skin, or the stability of the synthetic CoNS autoinducing 
peptide on the normal skin surface. Understanding the efficacy of long-term application of the 
synthetic autoinducing peptides or CoNS application onto epidermal models is essential for 
human therapeutic application. 
 
The data from the current study illustrate the complexity of interspecies and inter-kingdom 
communication on human skin by showing how multiple clinical CoNS isolates could prevent 
the capacity of S. aureus to induce skin barrier damage and inflammation. We showed that most, 
but not all, S. aureus colonies could induce epidermal damage. We also showed that the presence 
of live clinical CoNS isolates, or a synthetic autoinducing peptide identified in one strain, was 
protective against clinical S. aureus strains expressing PSMα. It is possible that additional, 
unknown chemical signals that regulate S. aureus agr activity may also exist on human skin. 
 
Together, we provide evidence that quorum sensing between some commensal CoNS species 
and S. aureus on human skin acts in a beneficial manner by inhibiting the negative consequences 
of S. aureus toxin production. This protective mechanism may act in parallel with the capacity of 
some CoNS strains to directly inhibit S. aureus survival (29). Because autoinducing peptide 
action does not limit S. aureus growth, evolutionary pressure to avoid agr inhibition is much 
different than the selective pressure for S. aureus to evolve antimicrobial resistance. By using 
both autoinducing peptide and antimicrobial strategies to compete with S. aureus, such CoNS 
strains could become a highly desirable member of the healthy human skin microbiome. These 
findings suggest that the pathophysiology of AD requires better knowledge of the failure of host 
skin to support these mutualistic relationships over the disease-promoting activity of S. aureus. 
Understanding how to optimize this may lead to improvements to existing therapeutic strategies. 
 




The objective of this study was to determine how components of the microbiome including S. 
aureus strains and CoNS species and strains promote or protect against epidermal damage in 
AD. This was done using commercial primary human keratinocytes, epicutaneous murine 
models, and bacteria harvested from human skin and through computational analysis of 
published skin microbiome sequencing. All experiments in this study using in vitro and in vivo 
techniques were carried out with a minimum n = 3 for biological replicates. Sample analysis was 
performed quantitatively, without assessment of power, in an unblinded manner and confirmed 
by at least two to three independent experiments as indicated in the figure legends. Primary data 
are reported in data file S1. 
 
Collection of bacteria from human subjects 
 
All experiments involving human subjects were carried out according to protocols approved by 
University of California, San Diego (UCSD) Institutional Review Board (project no. 071032). 
Skin swabs and bacteria isolates from healthy volunteers and patients with AD used in this study 
were collected from a previous study at UCSD under the protocol above with prior patient 
consent (29). Briefly, collection of surface bacteria was done from a premeasured area (15 cm2) 
of lesional skin on the antecubital crease of subjects with AD. Swabs were immediately placed 
into a 3% tryptic soy broth (TSB) and 16.67% glycerol solution and frozen at −80°C. For 
collection of clinical S. aureus and CoNS isolates, swabs were rapidly thawed, vortexed, and 
serially diluted onto mannitol salt agar selection plates supplemented with 3% egg yolk. S. 
aureus was distinguished from CoNS according to mannitol metabolism and the egg yolk 
reaction as described previously, and isolates were stored at −80°C in the same solution as above 
for further analyses (29, 41). Confirmation of species of select CoNS strains was identified by 




All bacteria used in this study are listed in table S1. All staphylococci (S. aureus and CoNS 
strains) were grown overnight (18 hours) to stationary phase in 3% TSB at 300 rpm in a 37°C 
incubator unless stated otherwise. This growth time for all staphylococci indicated about an 
OD600nm reading of 10 and 1 × 109 CFU. Specific strains were grown with antibiotic selection 
where indicated in table S1 at the following concentrations: Erm (5 μg/ml), Lcm (25 μg/ml), and 
Cm (10 μg/ml). For the treatment of bacterial supernatant on human keratinocytes or murine 
skin, bacteria cultured overnight were pelleted (15 min, 4000 rpm, room temperature) followed 
by filtered sterilization of the supernatant (0.22 μm). For mouse experiments with live bacteria 
colonization, bacterial CFU was approximated by OD600nm before application to mouse back skin 




NHEKs (Thermo Fisher Scientific) were cultured in EpiLife medium containing 60 μM 
CaCl2 (Thermo Fisher Scientific) supplemented with 1 EpiLife Defined Growth Supplement 
(Thermo Fisher Scientific) and 1× antibiotic-antimycotic [penicillin (100 U/ml), streptomycin 
(100 U/ml), amphotericin B (250 ng/ml); Thermo Fisher Scientific] at 37°C, 5% CO2. NHEKs 
were only used for experiments between passages 3 and 5. For experiments, NHEKs were grown 
to 70% confluency followed by differentiation in high-calcium EpiLife medium (2 mM CaCl2) 
for 48 hours to simulate the upper layers of the epidermis. For bacterial supernatant treatments, 
differentiated NHEKs were treated with sterile-filtered bacterial supernatant at 5% by volume to 
EpiLife medium for 24 hours. Similarly, for synthetic PSM treatments, the peptides (5 to 50 
μg/ml) were added to the NHEKs for 24 hours in dimethyl sulfoxide (DMSO). 
 
S. aureus epicutaneous mouse model 
 
Eight-week-old male C57BL/6 (The Jackson Laboratory) mice were used for all experiments 
(n = 5 to 6 per condition), as specified in the figure legends. Mice were co-housed with n = 3 to 5 
per cage for all experiments. All animal experiments were approved by the UCSD Institutional 
Animal Care and Use Committee (protocol no. S09074). Mouse hair was removed by shaving 
and applying Nair for 2 min followed by immediate removal with alcohol wipes. The skin barrier 
was allowed to recover from hair removal for 48 hours before application of bacteria. S. 
aureus (1 × 107 CFU) in 3% TSB was applied to murine skin for 48 to 72 hours at a 100-μl 
volume on a 2-cm2 piece of sterile gauze. Tegaderm was applied on top of gauze to hold in place 
for the duration of the treatment. For S. aureus agr inhibition experiments, live S. hominis C5 
(1:1) or synthetic autoinducing peptides (10 μg) were combined with S. aureus in 3% TSB 
immediately before application on gauze. 
 
Synthetic PSM preparation 
 
All synthetic PSMs were produced by LifeTein. Peptides were produced at 95% purity with N-
terminal formylation. PSM sequences were as follows: 
 
PSMα1, fMGIIAGIIKVIKSLIEQFTGK; PSMα2, fMGIIAGIIKFIKGLIEKFTGK; 
 




Peptides were resuspended in DMSO and concentrated by SpeedVac into 500 mg of powder 
stocks stored at −80°C before reconstitution in DMSO for experiments. 
 
S. hominis C5 autoinducing peptide structure determination 
 
We confirmed the structure of S. hominis C5 autoinducing peptide as S-Y-N-V-c(C-G-G-Y-F) 
(calculated m/z, 991.3984) as follows. S. hominis C5 was cultured for 24 hours in 3% TSB 
medium and was partially purified using solid-phase extraction as follows. The bacteria sterile-
filtered (0.22 μm) spent medium was inoculated with 80% ammonium sulfate for 1 hour 
followed by centrifugation and resuspension of the pellet in water. The fraction was further 
filtered using size-exclusion centrifugation and by collecting the <3-kDa filtrate followed by 
running the filtrate through a Sep Pak C18 column (Waters) collecting a 40% acetonitrile elution 
after discarding the flow through and 20% acetonitrile fractions. The 40% acetonitrile-eluted 
fraction was dried on a SpeedVac and resuspended in water. This partially purified fraction from 
the S. hominis C5 spent medium and medium-only control was analyzed in the positive ion mode 
using an Acquity ultra-performance liquid chromatography (UPLC) system (Waters Corp.) 
coupled to a Q Exactive Plus Orbitrap mass spectrometer (Thermo Fisher Scientific). The 
medium control and S. hominis C5 fraction were injected directly into the UPLC-MS system. 
Samples were analyzed using a 7.5-μl injection volume and a 10-min acetonitrile/water gradient 
as described previously (42). MS-MS data were collected by subjecting the [M + H]+-
ion m/z 991.3984 to higher-energy collisional dissociation (HCD) fragmentation with a 
normalized collision energy of 25. The S. hominis C5 autoinducing peptide sequence from the 
spent medium was determined to be S-Y-N-V-c(C-G-G-Y-F) and was synthesized by AnaSpec 
at 90% purity by high-performance liquid chromatography and resuspended in DMSO. The 
synthetic autoinducing peptide was confirmed to match the spent medium of S. hominis C5 
autoinducing peptide structure by running 0.05 mg/ml of the synthetic peptide side by side with 




To determine damage to the epidermal skin barrier, TEWL of murine skin treated for 48 to 72 
hours with S. aureus was measured using a Tewameter TM300 (C & K). 
 
Trypsin activity analysis 
 
NHEK conditioned medium was added at 50 μl to 96-well black-bottom plates (Corning) 
followed by addition of 150 μl of the peptide Boc-Val-Pro-Arg-AMC (trypsin-like substrate; 
Bachem) at a final concentration of 200 μM in 1× digestion buffer [10 mM tris-HCl (pH7.8)] and 
incubated at 37°C for 24 hours. Relative fluorescence intensity (excitation, 354 nm; emission, 
435 nm) was analyzed with a SpectraMax Gemini EM fluorometer (Thermo Fisher Scientific). 
For murine skin trypsin activity analysis, 0.5-cm2 full-thickness skin was bead-beat (2.0-mm 
zirconia beads, 2 × 30 s with 5 min after each) in 1 ml of 1 M acetic acid, followed by an 
overnight rotation at 4°C. Samples were centrifuged (10 min, 13,000 rpm, 4°C) and then added 
to a new microcentrifuge tube followed by protein concentration using a SpeedVac to remove all 
remaining acetic acid. Proteins were resuspended in molecular-grade water (500 μl) and rotated 
overnight at 4°C followed by another centrifugation. Clear protein lysates were added to a new 
tube, and bicinchoninic acid (Thermo Fisher Scientific) analysis was used to determine protein 
concentration. Last, 10 μg of total protein was added to a 96-well plate followed by analysis with 
the trypsin substrate as above. 
 
S. aureusagr activity 
 
Either the S. aureus USA300 LAC agr type I P3-YFP (AH1677) or the S. aureus USA300 LAC 
agr type I pAmi P3-Lux (AH2759) reporter strains were used to detect S. aureus agr activity. 
For in vitro experiments, S. aureus USA300 LAC agr type I P3-YFP diluted to 1 × 106 CFU and 
added to 300 μl of 3% TSB along with 100 μl of sterile-filtered commensal supernatant (25% by 
volume) was cultured overnight and shaken (300 rpm) for 24 hours at 37°C. Bacteria were then 
diluted 1:20 in phosphate-buffered saline (PBS) (200 μl final), and yellow fluorescent protein 
(YFP) (excitation, 495 nm; emission, 530 nm) was detected using the fluorometer as above. 
Bacterial density was determined using an OD600nm readout on a spectrophotometer. For murine 
experiments, S. aureus USA300 LAC agr type I pAmi P3-Lux luminescence activity was 
determined using a Spectrum IVIS machine. Luminescence intensity was assessed after an 
automatic 2-min exposure by measuring emitted photons (p/s/cm2/sr) using the Live Imaging 
software (PerkinElmer). 
 
Microbiome data and comparative genomic analysis 
 
We analyzed publicly available shotgun metagenomic data for AD skin (28). The relative 
abundance of S. aureus and S. epidermidis strains was obtained directly from the published 
supplementary material 
(www.sciencetranslationalmedicine.org/cgi/content/full/9/397/eaal4651/DC1). The agrD 
characterization analysis was performed on all 11 available AD patients with information at 
seven distinct body sites on flared AD skin (AD01 to AD11), with differences in AD severity 
based on oSCORAD. Both S. aureus and S. epidermidis strains detected from this dataset were 
classified by agr type through amino acid sequence comparison with known agr sequences 
within the agrD gene region (43). 
 
Quantification and statistical analysis 
 
The (nonparametric) unpaired Kruskal-Wallis test was used for statistical significance analysis of 
AD patient metagenomic data in Fig. 2G and AD skin swabs analysis of psmα expression in Fig. 
3H and fig. S4. All other figures used Student’s t tests and one-way analysis of variance 
(ANOVA) for statistical analysis, as indicated in the figure legends. All statistical analyses were 
performed using GraphPad Prism version 8.0 (GraphPad). All data were presented as means ± 




Materials and Methods 
Fig. S1. S. aureus PSMα changes essential barrier gene and cytokine expression in human 
keratinocytes. 
Fig. S2. S. aureus PSMα and proteases are responsible for barrier damage and induction of 
inflammation on murine skin. 
Fig. S3. Effect of AD skin disease severity on S. epidermidis agr type I to S. aureus relative 
abundance by body site. 
Fig. S4. Clinical CoNS isolates inhibit S. aureus agr activity without affecting growth. 
Fig. S5. S. hominis C5 live bacteria specifically inhibit S. aureus–mediated barrier damage and 
inflammation. 
Fig. S6. S. hominis C5 inhibits S. aureus agr types I to III but not type IV. 
Fig. S7. S. hominis C5 autoinducing peptide inhibits S. aureus–driven inflammation and barrier 
damage. 
Table S1. Bacteria strains and plasmids used. 
Table S2. Primers used for quantitative polymerase chain reaction and allelic replacement. 





Acknowledgments: We thank M. Otto (NIH) for providing the PSM knockout strains of S. 
aureus for this study and J. M. Kahlenberg (University of Michigan) for providing guidance on 
synthetic PSM production.  
 
Funding: This work was funded by The Atopic Dermatitis Research Network NIH U19 
AI117673 (to R.L.G.), R01AI116576 (to R.L.G.), R01AR064781 (to R.L.G.), T32AR062496 (to 
M.R.W.), R01AR064781-04S1 (to M.R.W.), VA I01 BX002711 (to A.R.H.), and R21 AI133089 
(to A.R.H.).  
 
Author contributions: M.R.W. wrote the manuscript and was responsible for designing and 
conducting the majority of the experiments. S.K.C. and A.L.C. developed the S. 
epidermidis RP62A autoinducing peptide knockout strain. L.S.Z. and K.Z. analyzed the AD 
metagenomic data. S.K. was responsible for helping with murine experiments and determination 
of S. aureus psmα expression. D.A.T., H.L.W., and N.B.C. determined the structure of S. 
hominis C5 autoinducing peptide. J.A.S., A.M.O., and M.C.L. helped with protein and mRNA 
expression experiments, while J.A.S. helped with RNA-seq analysis. T.N. provided project 
guidance and ideas and isolated the clinical CoNS strains used in this study. A.R.H. provided 
the S. aureus reporter strains used in this study as well as project guidance. R.L.G. conceived and 
interpreted experiments, wrote the manuscript, and supervised all aspects of this study.  
 
Competing interests: M.R.W. and R.L.G. are co-inventors of UCSD technology related to the 
bacterial quorum sensing inhibition therapy discussed here under patent PCT/US18/49237 titled 
“Molecular bacteriotherapy to control skin enzymatic activity.” R.L.G. is a co-founder, scientific 
advisor, consultant, and has equity in MatriSys Biosciences, and is a consultant, receives income 
from, and has equity in Sente.  
 
Data and materials availability: All data associated with this study are present in the paper or 
Supplementary Materials. RNA-seq data are available through the NCBI Gene Expression 
Omnibus (GEO) online data repository under accession number GSE124818. Bacterial genome 
sequences are available at NCBI BioProject under accession PRJNA514867. Primary data are 




1. L. Eckert, S. Gupta, C. Amand, A. Gadkari, P. Mahajan, J. M. Gelfand, The burden of atopic 
dermatitis in US adults: Health care resource utilization data from the 2013 National Health and 
Wellness Survey. J. Am. Acad. Dermatol. 78, 54–61.e1 (2018). 
 
2. S. Narla, D. Y. Hsu, J. P. Thyssen, J. I. Silverberg, Inpatient financial burden of atopic 
dermatitis in the United States. J. Invest. Dermatol. 137, 1461–1467 (2017). 
 
3. C. N. Palmer, A. D. Irvine, A. Terron-Kwiatkowski, Y. Zhao, H. Liao, S. P. Lee, D. R. 
Goudie, A. Sandilands, L. E. Campbell, F. J. Smith, G. M. O’Regan, R. M. Watson, J. E. Cecil, 
S. J. Bale, J. G. Compton, J. J. DiGiovanna, P. Fleckman, S. Lewis-Jones, G. Arseculeratne, A. 
Sergeant, C. S. Munro, B. El Houate, K. McElreavey, L. B. Halkjaer, H. Bisgaard, S. 
Mukhopadhyay, W. H. McLean, Common loss-of-function variants of the epidermal barrier 
protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 38, 441–446 
(2006). 
 
4. A. De Benedetto, N. M. Rafaels, L. Y. McGirt, A. I. Ivanov, S. N. Georas, C. Cheadle, A. E. 
Berger, K. Zhang, S. Vidyasagar, T. Yoshida, M. Boguniewicz, T. Hata, L. C. Schneider, J. M. 
Hanifin, R. L. Gallo, N. Novak, S. Weidinger, T. H. Beaty, D. Y. Leung, K. C. Barnes, L. A. 
Beck, Tight junction defects in patients with atopic dermatitis. J. Allergy Clin. Immunol. 127, 
773–786.e1-7 (2011). 
 
5. A. Kato, K. Fukai, N. Oiso, N. Hosomi, T. Murakami, M. Ishii, Association of SPINK5 gene 
polymorphisms with atopic dermatitis in the Japanese population. British J. Dermatol. 148, 665–
669 (2003). 
 
6. P. Meylan, C. Lang, S. Mermoud, A. Johannsen, S. Norrenberg, D. Hohl, Y. Vial, G. 
Prod'hom, G. Greub, M. Kypriotou, S. Christen-Zaech, Skin colonization by Staphylococcus 
aureus precedes the clinical diagnosis of atopic dermatitis in infancy. J. Invest. Dermatol. 137, 
2497–2504 (2017). 
 
7. E. A. Kennedy, J. Connolly, J. O. Hourihane, P. G. Fallon, W. H. McLean, D. Murray, J. H. 
Jo, J. A. Segre, H. H. Kong, A. D. Irvine, Skin microbiome before development of atopic 
dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a 
lower risk of atopic dermatitis at 1 year. J. Allergy Clin. Immunol. 139, 166–172 (2017). 
 
8. J. J. Leyden, R. R. Marples, A. M. Kligman, Staphylococcus aureus in the lesions of atopic 
dermatitis. Br. J. Dermatol. 90, 525–530 (1974).  
 
9. M. Alsterholm, L. Strombeck, A. Ljung, N. Karami, J. Widjestam, M. Gillstedt, C. Ahren, J. 
Faergemann, Variation in staphylococcus aureus colonization in relation to disease severity in 
adults with atopic dermatitis during a five-month follow-up. Acta Derm. Venereol. 97, 802–807 
(2017). 
 
10. J. Q. Gong, L. Lin, T. Lin, F. Hao, F. Q. Zeng, Z. G. Bi, D. Yi, B. Zhao, Skin colonization by 
Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined 
topical therapy: A double-blind multicentre randomized controlled trial. Br. J. Dermatol. 155, 
680–687 (2006). 
 
11. C. Pascolini, J. Sinagra, S. Pecetta, V. Bordignon, A. De Santis, L. Cilli, V. Cafiso, G. 
Prignano, B. Capitanio, C. Passariello, S. Stefani, P. Cordiali-Fei, F. Ensoli, Molecular and 
immunological characterization of Staphylococcus aureus in pediatric atopic dermatitis: 
Implications for prophylaxis and clinical management. Clin. Dev. Immunol. 2011, 718708 
(2011). 
 
12. T. Kawashima, E. Noguchi, T. Arinami, K. Yamakawa-Kobayashi, H. Nakagawa, F. Otsuka, 
H. Hamaguchi, Linkage and association of an interleukin 4 gene polymorphism with atopic 
dermatitis in Japanese families. J. Med. Genet. 35, 502–504 (1998). 
 
13. Y. Tsunemi, H. Saeki, K. Nakamura, T. Sekiya, K. Hirai, T. Kakinuma, H. Fujita, N. Asano, 
Y. Tanida, M. Wakugawa, H. Torii, K. Tamaki, Interleukin-13 gene polymorphism G4257A is 
associated with atopic dermatitis in Japanese patients. J. Dermatol. Sci. 30, 100–107 (2002). 
 
14. M. D. Howell, B. E. Kim, P. Gao, A. V. Grant, M. Boguniewicz, A. Debenedetto, L. 
Schneider, L. A. Beck, K. C. Barnes, D. Y. Leung, Cytokine modulation of atopic dermatitis 
filaggrin skin expression. J. Allergy Clin. Immunol. 120, 150–155 (2007). 
 
15. I. Nomura, E. Goleva, M. D. Howell, Q. A. Hamid, P. Y. Ong, C. F. Hall, M. A. Darst, B. 
Gao, M. Boguniewicz, J. B. Travers, D. Y. Leung, Cytokine milieu of atopic dermatitis, as 
compared to psoriasis, skin prevents induction of innate immune response genes. J. Immunol. 
171, 3262–3269 (2003). 
 
16. A. Tsianakas, T. A. Luger, The anti-IL-4 receptor alpha antibody dupilumab: Facing a new 
era in treating atopic dermatitis. Expert Opin. Biol. Ther. 15, 1657–1660 (2015). 
 
17. H. Liu, N. K. Archer, C. A. Dillen, Y. Wang, A. G. Ashbaugh, R. V. Ortines, T. Kao, S. K. 
Lee, S. S. Cai, R. J. Miller, M. C. Marchitto, E. Zhang, D. P. Riggins, R. D. Plaut, S. Stibitz, R. 
S. Geha, L. S. Miller, Staphylococcus aureus epicutaneous exposure drives skin inflammation 
via IL-36-mediated T cell responses. Cell Host Microbe 22, 653–666.e5 (2017). 
 
18. S. Nakagawa, M. Matsumoto, Y. Katayama, R. Oguma, S. Wakabayashi, T. Nygaard, S. 
Saijo, N. Inohara, M. Otto, H. Matsue, G. Nunez, Y. Nakamura, Staphylococcus aureus virulent 
PSMα peptides induce keratinocyte alarmin release to orchestrate IL-17-dependent skin 
inflammation. Cell Host Microbe 22, 667–677.e5 (2017). 
 
19. Y. Nakamura, J. Oscherwitz, K. B. Cease, S. M. Chan, R. Munoz-Planillo, M. Hasegawa, A. 
E. Villaruz, G. Y. Cheung, M. J. McGavin, J. B. Travers, M. Otto, N. Inohara, G. Nunez, 
Staphylococcus δ-toxin induces allergic skin disease by activating mast cells. Nature 503, 397–
401 (2013). 
 
20. A. K. Syed, T. J. Reed, K. L. Clark, B. R. Boles, J. M. Kahlenberg, Staphylococcus aureus 
phenol-soluble modulins stimulate the release of proinflammatory cytokines from keratinocytes 
and are required for induction of skin inflammation. Infect. Immun. 83, 3428–3437 (2015). 
 
21. M. R. Williams, T. Nakatsuji, J. A. Sanford, A. F. Vrbanac, R. L. Gallo, Staphylococcus 
aureus induces increased serine protease activity in keratinocytes. J. Invest. Dermatol. 137, 377–
384 (2017). 
 
22. T. Nakatsuji, T. H. Chen, A. M. Two, K. A. Chun, S. Narala, R. S. Geha, T. R. Hata, R. L. 
Gallo, Staphylococcus aureus exploits epidermal barrier defects in atopic dermatitis to trigger 
cytokine expression. J. Invest. Dermatol. 136, 2192–2200 (2016). 
 
23. T. Nakatsuji, H. I. Chiang, S. B. Jiang, H. Nagarajan, K. Zengler, R. L. Gallo, The 
microbiome extends to subepidermal compartments of normal skin. Nat. Commun. 4, 1431 
(2013). 
 
24. M. E. Wormann, N. T. Reichmann, C. L. Malone, A. R. Horswill, A. Grundling, Proteolytic 
cleavage inactivates the Staphylococcus aureus lipoteichoic acid synthase. J. Bacteriol. 193, 
5279–5291 (2011). 
 
25. H. J. Chung, H. S. Jeon, H. Sung, M. N. Kim, S. J. Hong, Epidemiological characteristics of 
methicillin-resistant Staphylococcus aureus isolates from children with eczematous atopic 
dermatitis lesions. J. Clin. Microbiol. 46, 991–995 (2008). 
 
26. H. Lomholt, K. E. Andersen, M. Kilian, Staphylococcus aureus clonal dynamics and 
virulence factors in children with atopic dermatitis. J. Invest. Dermatol. 125, 977–982 (2005). 
 
27. M. Otto, H. Echner, W. Voelter, F. Gotz, Pheromone cross-inhibition between 
Staphylococcus aureus and Staphylococcus epidermidis. Infect. Immun. 69, 1957–1960 (2001). 
 
28. A. L. Byrd, C. Deming, S. K. B. Cassidy, O. J. Harrison, W. I. Ng, S. Conlan, NISC 
Comaprative Sequencing Program, Y. Belkaid, J. A. Segre, H. H. Kong, Staphylococcus aureus 
and Staphylococcus epidermidis strain diversity underlying pediatric atopic dermatitis. Sci. 
Transl. Med. 9, eaal4651 (2017). 
 
29. T. Nakatsuji, T. H. Chen, S. Narala, K. A. Chun, A. M. Two, T. Yun, F. Shafiq, P. F. Kotol, 
A. Bouslimani, A. V. Melnik, H. Latif, J. N. Kim, A. Lockhart, K. Artis, G. David, P. Taylor, J. 
Streib, P. C. Dorrestein, A. Grier, S. R. Gill, K. Zengler, T. R. Hata, D. Y. Leung, R. L. Gallo, 
Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and 
are deficient in atopic dermatitis. Sci. Transl. Med. 9, eaah4680 (2017). 
 
30. B. A. Khan, A. J. Yeh, G. Y. Cheung, M. Otto, Investigational therapies targeting quorum-
sensing for the treatment of Staphylococcus aureus infections. Expert Opin. Investig. Drugs 24, 
689–704 (2015). 
 
31. J. Canovas, M. Baldry, M. S. Bojer, P. S. Andersen, B. H. Gless, P. K. Grzeskowiak, M. 
Stegger, P. Damborg, C. A. Olsen, H. Ingmer, Corrigendum: Cross-talk between Staphylococcus 
aureus and other staphylococcal species via the agr quorum sensing system. Front. Microbiol. 8, 
1949 (2017). 
 
32. A. E. Paharik, C. P. Parlet, N. Chung, D. A. Todd, E. I. Rodriguez, M. J. Van Dyke, N. B. 
Cech, A. R. Horswill, Coagulase-negative staphylococcal strain prevents Staphylococcus aureus 
colonization and skin infection by blocking quorum sensing. Cell Host Microbe 22, 746–756.e5 
(2017). 
 
33. Y. Hirasawa, T. Takai, T. Nakamura, K. Mitsuishi, H. Gunawan, H. Suto, T. Ogawa, X. L. 
Wang, S. Ikeda, K. Okumura, H. Ogawa, Staphylococcus aureus extracellular protease causes 
epidermal barrier dysfunction. J. Invest. Dermatol. 130, 614–617 (2010). 
 
34. A. Di Cesare, P. Di Meglio, F. O. Nestle, A role for Th17 cells in the immunopathogenesis of 
atopic dermatitis? J. Invest. Dermatol. 128, 2569–2571 (2008). 
 
35. H. Esaki, P. M. Brunner, Y. Renert-Yuval, T. Czarnowicki, T. Huynh, G. Tran, S. Lyon, G. 
Rodriguez, S. Immaneni, D. B. Johnson, B. Bauer, J. Fuentes-Duculan, X. Zheng, X. Peng, Y. D. 
Estrada, H. Xu, C. de Guzman Strong, M. Suarez-Farinas, J. G. Krueger, A. S. Paller, E. 
Guttman-Yassky, Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. 
J. Allergy Clin. Immunol. 138, 1639–1651 (2016). 
 
36. C. Koga, K. Kabashima, N. Shiraishi, M. Kobayashi, Y. Tokura, Possible pathogenic role of 
Th17 cells for atopic dermatitis. J. Invest. Dermatol. 128, 2625–2630 (2008). 
 
37. B. R. Boles, A. R. Horswill, Agr-mediated dispersal of Staphylococcus aureus biofilms. 
PLOS Pathog. 4, e1000052 (2008). 
 
38. C. Vuong, H. L. Saenz, F. Gotz, M. Otto, Impact of the agr quorum-sensing system on 
adherence to polystyrene in Staphylococcus aureus. J. Infect. Dis. 182, 1688–1693 (2000). 
 
39. H. B. Allen, N. D. Vaze, C. Choi, T. Hailu, B. H. Tulbert, C. A. Cusack, S. G. Joshi, The 
presence and impact of biofilm-producing staphylococci in atopic dermatitis. JAMA Dermatol. 
150, 260–265 (2014). 
 
40. A. Sonesson, K. Przybyszewska, S. Eriksson, M. Morgelin, S. Kjellstrom, J. Davies, J. 
Potempa, A. Schmidtchen, Identification of bacterial biofilm and the Staphylococcus aureus 
derived protease, staphopain, on the skin surface of patients with atopic dermatitis. Sci. Rep. 7, 
8689 (2017). 
 
41. T. Iwase, Y. Uehara, H. Shinji, A. Tajima, H. Seo, K. Takada, T. Agata, Y. Mizunoe, 
Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal 
colonization. Nature 465, 346–349 (2010). 
 
42. D. A. Todd, C. P. Parlet, H. A. Crosby, C. L. Malone, K. P. Heilmann, A. R. Horswill, N. B. 
Cech, Signal biosynthesis inhibition with ambuic acid as a strategy to target antibiotic-resistant 
infections. Antimicrob. Agents Chemother. 61, (2017). 
 
43. M. E. Olson, D. A. Todd, C. R. Schaeffer, A. E. Paharik, M. J. Van Dyke, H. Buttner, P. M. 
Dunman, H. Rohde, N. B. Cech, P. D. Fey, A. R. Horswill, Staphylococcus epidermidis agr 
quorum-sensing system: Signal identification, cross talk, and importance in colonization. J. 
Bacteriol. 196, 3482–3493 (2014). 
 
44. S. K. Costa, N. P. Donegan, A. R. Corvaglia, P. Francois, A. L. Cheung, Bypassing the 
restriction system to improve transformation of Staphylococcus epidermidis. J. Bacteriol. 199, 
e00271-17 (2017). 
 
45. I. R. Monk, I. M. Shah, M. Xu, M. W. Tan, T. J. Foster, Transforming the untransformable: 
Application of direct transformation to manipulate genetically Staphylococcus aureus and 
Staphylococcus epidermidis. MBio 3, e00277-11 (2012). 
 
46. M. Arnaud, A. Chastanet, M. Debarbouille, New vector for efficient allelic replacement in 
naturally nontransformable, low-GC-content, gram-positive bacteria. Appl. Environ. Microbiol. 
70, 6887–6891 (2004). 
 
47. B. Langmead, S. L. Salzberg, Fast gapped-read alignment with bowtie 2. Nat. Methods 9, 
357–359 (2012). 
 
48. A. Bankevich, S. Nurk, D. Antipov, A. A. Gurevich, M. Dvorkin, A. S. Kulikov, V. M. 
Lesin, S. I. Nikolenko, S. Pham, A. D. Prjibelski, A. V. Pyshkin, A. V. Sirotkin, N. Vyahhi, G. 
Tesler, M. A. Alekseyev, P. A. Pevzner, SPAdes: A new genome assembly algorithm and its 
applications to single-cell sequencing. J. Comput. Biol. 19, 455–477 (2012). 
 
49. R. Overbeek, R. Olson, G. D. Pusch, G. J. Olsen, J. J. Davis, T. Disz, R. A. Edwards, S. 
Gerdes, B. Parrello, M. Shukla, V. Vonstein, A. R. Wattam, F. Xia, R. Stevens, The SEED and 
the rapid annotation of microbial genomes using subsystems technology (RAST). Nucleic Acids 
Res. 42, D206–D214 (2013S). 
 
50. M. Thoendel, J. S. Kavanaugh, C. E. Flack, A. R. Horswill, Peptide signaling in the 
staphylococci. Chem. Rev. 111, 117–151 (2011). 
 
51. P. Gilot, G. Lina, T. Cochard, B. Poutrel, Analysis of the genetic variability of genes 
encoding the RNA III-activating components Agr and TRAP in a population of Staphylococcus 
aureus strains isolated from cows with mastitis. J. Clin. Microbiol. 40, 4060–4067 (2002). 
 
52. R. Wang, K. R. Braughton, D. Kretschmer, T. H. Bach, S. Y. Queck, M. Li, A. D. Kennedy, 
D. W. Dorward, S. J. Klebanoff, A. Peschel, F. R. DeLeo, M. Otto, Identification of novel 
cytolytic peptides as key virulence determinants for community-associated MRSA. Nat. Med. 13, 
1510–1514 (2007). 
 
53. M. Figueroa, A. K. Jarmusch, H. A. Raja, T. El-Elimat, J. S. Kavanaugh, A. R. Horswill, R. 
G. Cooks, N. B. Cech, N. H. Oberlies, Polyhydroxyanthraquinones as quorum sensing inhibitors 
from the guttates of Penicillium restrictum and their analysis by desorption electrospray 
ionization mass spectrometry. J. Nat. Prod. 77, 1351–1358 (2014). 
 
54. A. Muhs, J. T. Lyles, C. P. Parlet, K. Nelson, J. S. Kavanaugh, A. R. Horswill, C. L. Quave, 
Virulence inhibitors from Brazilian peppertree block quorum sensing and abate dermonecrosis in 
skin infection models. Sci. Rep. 7, 42275 (2017). 
 
55. C. L. Malone, B. R. Boles, K. J. Lauderdale, M. Thoendel, J. S. Kavanaugh, A. R. Horswill, 
Fluorescent reporters for Staphylococcus aureus. J. Microbiol. Methods 77, 251–260 (2009). 
 
56. E. K. Sully, N. Malachowa, B. O. Elmore, S. M. Alexander, J. K. Femling, B. M. Gray, F. R. 
DeLeo, M. Otto, A. L. Cheung, B. S. Edwards, L. A. Sklar, A. R. Horswill, P. R. Hall, H. D. 
Gresham, Selective chemical inhibition of agr quorum sensing in Staphylococcus aureus 
promotes host defense with minimal impact on resistance. PLOS Pathog. 10, e1004174 (2014). 
